Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Antibody
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 311804
License Grant
Irish Licensee has a license with Licensor for the development and U.S. commercialization of Zepzelca.
License Property
Zepzelcaâ„¢ (lurbinectedin), a product approved by FDA in June 2020 and recently launched in the U.S. for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy.
Licensor is a company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. An integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer.
Field of Use
The Field of Use is for the treatment of lung cancer in adult patients specifically SCLC (small cell lung cancer).
Licensee is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases – often with limited or no options.
IPSCIO Record ID: 386935
License Grant
The parties collaborated to create and develop bispecific antibodies using Licensor’s DuoBody technology platform.
Under this original agreement, Licensee had the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations.
Licensee received approval from the FDA for amivantamab, as RYBREVANT, a therapy that was created using Danish Licensor’s proprietary DuoBody bispecific technology platform.
License Property
Amivantamab has been approved in the United States and the European Union under the name RYBREVANT for the treatment of certain adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with epidermal growth factor receptor (“EGFRâ€) exon 20 insertion mutations. The two antibody libraries used to produce amivantamab were both generated by Licensor. The antibody pair used to create amivantamab was selected in collaboration between the parties.
Field of Use
The rights grants is used for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Amivantamab, created using Licensor’s DuoBody technology platform is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets.
IPSCIO Record ID: 322039
License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.
Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.
License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.
Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.
HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.
Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.
Field of Use
The field of use is for the treatment of cancer such as breast cancer.
HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).
Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.
IPSCIO Record ID: 321858
License Grant
This amendment increases the royalties for dostarlimab and adds terms for Zejula.
License Property
Dostarlimab is an anti-PD-1 antagonist antibody.
Zejula TM is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor.
Field of Use
Dostarlimab is under development for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors.
Zejula, which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
IPSCIO Record ID: 256273
License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.
This agreement includes a non-exclusive grant by Licensee to Licensor.
License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.
The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.
Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.
Field of Use
The Field means the treatment of human diseases, disorders and conditions.
IPSCIO Record ID: 1364
License Grant
We entered into a broad collaboration with Licensee for the discovery, development and commercialization of novel small molecule therapeutics in the areas of vascular biology, inflammatory disease and cancer, to the extent not previously partnered.
License Property
In accordance with the 2002 collaboration Agreement with the Licensor, the Licensee is required to pay them a royalty on the Net Sales of any product incorporating cabozantinib, including Cometriq.
Field of Use
Cometriq was approved by the FDA for the treatment of progressive, metastatic MTC in the United States in November 2012.
The Licensee commercially launched Cometriq in late January 2013.
The Licensee currently estimates that there are between 500 and 700 first and second line metastatic MTC patients in the United States each year who will be eligible for Cometriq, and as a result only expect to generate limited revenues from the sale of Cometriq in the near term.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
